Edesa finds a signal in severely ill Covid-19 patients

The doubling in value of tiny Edesa Biotech yesterday on mid-stage Covid-19 data in a handful of patients shows that there is still interest in new therapies for the coronavirus, particularly in the inpatient setting.

Edesa is already making its plans for further trials and expedited review of its anti-toll-like receptor 4 MAb EB05. Other small biotechs are already testing assets with a range of mechanisms in phase 3 or large-scale phase 2 studies.